Results 1-20 of 1,475 for drugs speaker:Stephen Donnelly

Written Answers — Department of Health: Cannabis for Medicinal Use (30 Apr 2024)

Stephen Donnelly: The receipt and processing of applications from clinicians to the Minister for Health for a licence issued pursuant to Section 14 of the Misuse of Drugs Act to treat a patient with cannabis-based products is solely a matter for the Department of Health.

Written Answers — Department of Health: Cannabis for Medicinal Use (30 Apr 2024)

Stephen Donnelly: An application for a licence issued pursuant to Section 14 of the Misuse of Drugs Act to treat a patient with cannabis-based products may only be made by a consultant or a general practitioner with the endorsement of a consultant. A patient may not make an application for a licence. The Department of Health will only discuss the application with the applicant and not with any third party,...

Written Answers — Department of Health: Cannabis for Medicinal Use (30 Apr 2024)

Stephen Donnelly: An application for a licence issued pursuant to Section 14 of the Misuse of Drugs Act to treat a patient with cannabis-based products may be made by a consultant or a general practitioner with the endorsement of a consultant. The Department of Health will only discuss the application with the applicant and has no record of an application being made to the Minister for Health by the person...

Written Answers — Department of Health: Cannabis for Medicinal Use (30 Apr 2024)

Stephen Donnelly: A consultant or a GP with the endorsement of a consultant may apply to the Minister for Health for a licence issued pursuant to Section 14 of the Misuse of Drugs Act to treat a patient with cannabis-based products. The Department will only discuss the application with the applicant and not with any third parties, which includes patients. A patient may discuss the matter directly with their...

Written Answers — Department of Health: Cannabis for Medicinal Use (30 Apr 2024)

Stephen Donnelly: A consultant who has submitted valid application to the Minister for Health for a licence issued pursuant to Section 14 of the Misuse of Drugs Act to treat a patient with cannabis-based products can expect to hear from the Department of Health within a matter of days.

Written Answers — Department of Health: Health Services (30 Apr 2024)

Stephen Donnelly: ...policy, legislation and investment to deliver expanded eligibility. In 2022, a range of measures were delivered including the abolition of public in-patient charges for children, reductions in the Drug Payment Scheme threshold to €80 per month, and the introduction of free contraception for women aged 17-25. In 2023, further measures have facilitated better access to...

Written Answers — Department of Health: Health Services (30 Apr 2024)

Stephen Donnelly: I propose to take Questions Nos. 734 and 741 together. Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the administration of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Written Answers — Department of Health: Medicinal Products (25 Apr 2024)

Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for pricing and reimbursement decisions under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. The HSE advise that the following pain relief patches are currently available on the reimbursement list: Durogesic DTrans Transdermal patches Fental Matrix Transdermal patches...

Written Answers — Department of Health: Health Services (23 Apr 2024)

Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for pricing and reimbursement decisions under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. The HSE advise that the following pain relief patches are currently available on the reimbursement list: Durogesic DTrans Transdermal patches Fental Matrix Transdermal patches...

Written Answers — Department of Health: Substance Misuse (23 Apr 2024)

Stephen Donnelly: ...to open with an explanation as to what HHC is and its current legal position. Tetrahydrocannabinol, known as THC, is the principal psychoactive constituent of cannabis, is a Schedule 1 controlled drug in the Misuse of Drugs Regulations and is subject to the strictest of controls. Hexahydrocannabinol (HHC) is a derivative of tetrahydrocannabinol (THC) but it is not a Schedule 1...

Written Answers — Department of Health: Medicinal Products (23 Apr 2024)

Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013. Reimbursement is for licensed indications which have been granted market authorisation by the European Medicines Agency (EMA) or the Health...

Written Answers — Department of Health: Medicinal Products (17 Apr 2024)

Stephen Donnelly: ..., a company must first submit an application to the HSE to have a new medicine added to the reimbursement list. All medicines which have been added to the reimbursement list, including cancer drug therapies, are available to eligible patients in the public health service.

Written Answers — Department of Health: Medical Aids and Appliances (16 Apr 2024)

Stephen Donnelly: ..., legislation and investment to deliver expanded eligibility. In 2022, a range of measures were delivered including the abolition of public in-patient charges for children, reductions in the Drug Payment Scheme threshold to €80 per month, and the introduction of free contraception for women aged 17-25. In 2023, further measures have facilitated better access to...

Written Answers — Department of Health: Health Services (16 Apr 2024)

Stephen Donnelly: ...; diabetes mellitus; parkinsonism; epilepsy; phenylketonuria; haemophilia; spina bifida; hydrocephalus; and conditions arising from the use of Thalidomide. Under the LTI Scheme, patients receive drugs, medicines, and medical and surgical appliances directly related to the treatment of their illness, free of charge. There are currently no plans to extend the list of conditions. People...

Written Answers — Department of Health: Departmental Schemes (11 Apr 2024)

Stephen Donnelly: ..., legislation and investment to deliver expanded eligibility. In 2022, a range of measures were delivered including the abolition of public in-patient charges for children, reductions in the Drug Payment Scheme threshold to €80 per month, and the introduction of free contraception for women aged 17-25. In 2023, further measures have facilitated better access to...

Written Answers — Department of Health: Departmental Licences (10 Apr 2024)

Stephen Donnelly: A Ministerial Licence issued pursuant to Section 14 of the Misuse of Drugs Act 1977, entitles the clinician licence holder to prescribe, import, supply, possess and administer a Schedule 1 controlled drug in the treatment of their patient. The treatment of their patient by a licensed Doctor is a clinical matter and the disclosure of any confidential information, such as the condition...

Written Answers — Department of Health: Social Welfare Schemes (9 Apr 2024)

Stephen Donnelly: ..., legislation and investment to deliver expanded eligibility. In 2022, a range of measures were delivered including the abolition of public in-patient charges for children, reductions in the Drug Payment Scheme threshold to €80 per month, and the introduction of free contraception for women aged 17-25. In 2023, further measures have facilitated better access to...

Written Answers — Department of Health: Health Services (9 Apr 2024)

Stephen Donnelly: ..., legislation and investment to deliver expanded eligibility. In 2022, a range of measures were delivered including the abolition of public in-patient charges for children, reductions in the Drug Payment Scheme threshold to €80 per month, and the introduction of free contraception for women aged 17-25. In 2023, further measures have facilitated better access to...

Written Answers — Department of Health: Medicinal Products (9 Apr 2024)

Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013. Reimbursement is for licensed indications which have been granted market authorisation by the European Medicines Agency (EMA) or the Health...

Written Answers — Department of Health: Health Services (21 Mar 2024)

Stephen Donnelly: ...timely applications from industry. Alongside the approval of additional resources for the agencies involved in the HSE’s medicines pricing and reimbursement system, The HSE will have €30 million to spend on new drugs in 2024. This comprises €20 million of new development funding and a further €10 million, to be generated through HSE efficiencies, which will...